Complete Summary

TITLE

Child and adolescent major depressive disorder: percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with a plan for follow-up care documented.

SOURCE(S)

Physician Consortium for Performance Improvement®. Child and adolescent major depressive disorder physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2008 Sep. 30 p. [13 references]

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with a plan for follow-up care documented.

RATIONALE

Given the high drop-out rate among children and adolescents who begin treatment, it is critical that a plan be established to continue and monitor treatment.

The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure:

During all treatment phases, clinicians should arrange frequent follow-up contacts that allow sufficient time to monitor the subject's clinical status, environmental conditions, and, if appropriate, medication side effects. (American Academy of Child and Adolescent Psychiatry [AACAP], 2007)

It is recommended that all patients receiving [antidepressants] be carefully monitored for suicidal thoughts and behavior, as well as other side effects thought to be possibly associated with increased suicidality, particularly during the first weeks of treatment. The Food and Drug Administration (FDA) recommends that depressed youth should be seen every week for the first 4 weeks and biweekly thereafter. However, it is not always possible to schedule weekly face-to-face appointments. In this case, evaluations should be briefly carried out by phone, but it is important to emphasize that there is no data to suggest that the monitoring schedule proposed by the FDA or telephone calls have any impact on the risk of suicide. Monitoring is important for all patients, but patients at increased risk for suicide (e.g., those with current or prior suicidality, impulsivity, substance abuse, history of sexual abuse, family history of suicide) should be scrutinized particularly closely. (AACAP, 2007)

The treatment of depressive disorders should always include an acute and continuation phase. Some children may also require maintenance treatment. (AACAP, 2007)

To consolidate the response to the acute treatment and avoid relapses, treatment should always be continued for 6 to 12 months. (AACAP, 2007)

PRIMARY CLINICAL COMPONENT

Child and adolescent major depressive disorder; follow-up care plan

DENOMINATOR DESCRIPTION

All patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder

Note: Refer to the original measure documentation for administrative codes.

NUMERATOR DESCRIPTION

Patient visits with a plan for follow-up care documented

Note: Refer to the original measure documentation for administrative codes.

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

NATIONAL GUIDELINE CLEARINGHOUSE LINK

- Practice parameters for the assessment and treatment of children and adolescents with depressive disorders.

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Individual Clinicians

TARGET POPULATION AGE

Ages 6 through 17 years

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Unspecified

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness

Data Collection for the Measure

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

All patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions
All patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder

Note: Refer to the original measure documentation for administrative codes.

Exclusions
None

RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

DENOMINATOR (INDEX) EVENT

Clinical Condition
Encounter

DENOMINATOR TIME WINDOW

Time window is a single point in time

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions
Patient visits with a plan for follow-up care documented

Note: Refer to the original measure documentation for administrative codes.

Exclusions
None

MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

NUMERATOR TIME WINDOW

Encounter or point in time

DATA SOURCE

Administrative data
Medical record

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

Unspecified

Identifying Information

ORIGINAL TITLE

Measure #6: follow-up care.

MEASURE COLLECTION

The Physician Consortium for Performance Improvement® Measurement Sets

MEASURE SET NAME

Child and Adolescent Major Depressive Disorder Physician Performance Measurement Set

SUBMITTER

American Medical Association on behalf of the Physician Consortium for Performance Improvement®

DEVELOPER

Physician Consortium for Performance Improvement®

FUNDING SOURCE(S)

Unspecified

COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

Richard Hellman, MD, FACP, FACE (*Co-chair*) (methodologist; clinical endocrinology); John Oldham, MD (*Co-chair*) (psychiatry); Boris Birmaher, MD (child/adolescent psychiatry); Mary Dobbins, MD, FAAP (pediatrics/psychiatry); Scott Endsley, MD, MSc (family medicine); William E. Golden, MD, FACP (internal medicine); Margaret L. Keeler, MD, MS, FACEP (emergency, medicine); Louis J. Kraus, MD (child/adolescent psychiatry); Laurent S. Lehmann, MD (psychiatry); Karen Pierce, MD (child/adolescent psychiatry); Reed E. Pyeritz, MD, PhD, FACP, FACMG (medical genetics); Laura Richardson, MD, MPH (internal medicine/pediatrics); Sam J.W. Romeo, MD, MBA (family medicine); Carl A. Sirio, MD (critical care medicine); Sharon Sweede, MD (family medicine); Scott Williams, PsyD (The Joint Commission)

American Medical Association: Heidi Bossley, MSN, MBA; Joseph Gave, MPH; Karen Kmetik, PhD; Shannon Sims, MD, PhD; Samantha Tierney, MPH

American Psychiatric Association: Robert Plovnick, MD, MS

National Committee for Quality Assurance: Phil Renner, MBA

Consultants: Timothy Kresowik, MD; Rebecca Kresowik

FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement® conflict of interest policy.

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2008 Sep

MEASURE STATUS

This is the current release of the measure.

SOURCE(S)

Physician Consortium for Performance Improvement®. Child and adolescent major depressive disorder physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2008 Sep. 30 p. [13 references]

MEASURE AVAILABILITY

The individual measure, "Measure #6: Follow-Up Care," is published in "Child and Adolescent Major Depressive Disorder Physician Performance Measurement Set." This document and technical specifications are available in Portable Document Format (PDF) from the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement® Web site: www.physicianconsortium.org.

For further information, please contact AMA staff by e-mail at cqi@ama-assn.org.

NQMC STATUS

This NQMC summary was completed by ECRI Institute on March 2, 2009. The information was verified by the measure developer on April 13, 2009.

COPYRIGHT STATEMENT

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

Date Modified: 5/18/2009